Glaukos Co. (NYSE:GKOS) Position Increased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC increased its position in shares of Glaukos Co. (NYSE:GKOS) by 39.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 29,790 shares of the medical instruments supplier’s stock after buying an additional 8,460 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Glaukos were worth $4,467,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of GKOS. IFP Advisors Inc purchased a new stake in shares of Glaukos during the fourth quarter worth $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter worth $90,000. Harvest Fund Management Co. Ltd raised its holdings in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after buying an additional 860 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in Glaukos during the fourth quarter valued at about $153,000. Finally, Smartleaf Asset Management LLC raised its holdings in Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock valued at $164,000 after buying an additional 807 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on GKOS shares. Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group started coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 target price on the stock. Needham & Company LLC raised their target price on Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a report on Friday, February 21st. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Monday, December 2nd. Finally, Stifel Nicolaus raised their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Stock Down 7.9 %

GKOS stock opened at $103.30 on Friday. Glaukos Co. has a twelve month low of $84.08 and a twelve month high of $163.71. The company has a market cap of $5.84 billion, a PE ratio of -35.99 and a beta of 1.04. The business’s 50-day simple moving average is $147.87 and its 200 day simple moving average is $139.14. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,744 shares of company stock valued at $2,792,151. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.